India, Nov. 5 -- Hyderabad-based Dr. Reddy's Laboratories has announced that Brazil's National Health Surveillance Agency (ANVISA) has granted marketing authorisation for generic semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise, either as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.

The product will be available as a pre-filled, multi-dose injectable pen in two presentations, 2 mg/1.5 mL and 4 mg/3 mL, for once-weekly dosing.

Brazil has 16.6 million adults aged 20-79 living with diabetes and ranks sixth globally in terms o...